These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30233802)

  • 1. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Cottin V
    BMJ Open Respir Res; 2018; 5(1):e000289. PubMed ID: 30233802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use.
    Kreuter M; Maher TM; Corte TJ; Molina-Molina M; Axmann J; Gilberg F; Kirchgaessler KU; Cottin V
    Adv Ther; 2022 Feb; 39(2):1081-1095. PubMed ID: 34936057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a
    Molina-Molina M; Kreuter M; Cottin V; Corte TJ; Gilberg F; Kirchgaessler KU; Axmann J; Maher TM
    Front Med (Lausanne); 2022; 9():897102. PubMed ID: 35783648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
    Solomon JJ; Danoff SK; Woodhead FA; Hurwitz S; Maurer R; Glaspole I; Dellaripa PF; Gooptu B; Vassallo R; Cox PG; Flaherty KR; Adamali HI; Gibbons MA; Troy L; Forrest IA; Lasky JA; Spencer LG; Golden J; Scholand MB; Chaudhuri N; Perrella MA; Lynch DA; Chambers DC; Kolb M; Spino C; Raghu G; Goldberg HJ; Rosas IO;
    Lancet Respir Med; 2023 Jan; 11(1):87-96. PubMed ID: 36075242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD).
    Maher TM; Assassi S; Azuma A; Cottin V; Hoffmann-Vold AM; Kreuter M; Oldham JM; Richeldi L; Valenzuela C; Wijsenbeek MS; Coeck C; Schlecker C; Voss F; Wachtlin D; Martinez FJ
    BMJ Open Respir Res; 2023 Sep; 10(1):. PubMed ID: 37709661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.
    Flaherty KR; Brown KK; Wells AU; Clerisme-Beaty E; Collard HR; Cottin V; Devaraj A; Inoue Y; Le Maulf F; Richeldi L; Schmidt H; Walsh S; Mezzanotte W; Schlenker-Herceg R
    BMJ Open Respir Res; 2017; 4(1):e000212. PubMed ID: 29018526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline.
    Nagy A; Nagy T; Kolonics-Farkas AM; Eszes N; Vincze K; Barczi E; Tarnoki AD; Tarnoki DL; Nagy G; Kiss E; Maurovich-Horvat P; Bohacs A; Müller V
    Front Pharmacol; 2021; 12():778649. PubMed ID: 35002713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial.
    Popmihajlov Z; Sutherland DJ; Horan GS; Ghosh A; Lynch DA; Noble PW; Richeldi L; Reiss TF; Greenberg S
    BMJ Open Respir Res; 2022 Jan; 9(1):. PubMed ID: 35058236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
    Solomon JJ; Danoff SK; Goldberg HJ; Woodhead F; Kolb M; Chambers DC; DiFranco D; Spino C; Haynes-Harp S; Hurwitz S; Peters EB; Dellaripa PF; Rosas IO;
    Adv Ther; 2019 Nov; 36(11):3279-3287. PubMed ID: 31515704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis.
    Fernández Pérez ER; Crooks JL; Swigris JJ; Solomon JJ; Mohning MP; Huie TJ; Koslow M; Lynch DA; Groshong SD; Fier K
    ERJ Open Res; 2021 Apr; 7(2):. PubMed ID: 34109243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Functional Characteristics of Patients with Unclassifiable Interstitial Lung Disease (uILD): Long-Term Follow-Up Data from European IPF Registry (eurIPFreg).
    Krauss E; El-Guelai M; Pons-Kuehnemann J; Dartsch RC; Tello S; Korfei M; Mahavadi P; Breithecker A; Fink L; Stoehr M; Majeed RW; Seeger W; Crestani B; Guenther A
    J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32756496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
    Markart P; Drakopanagiotakis F; Wygrecka M
    Dtsch Med Wochenschr; 2021 Feb; 146(3):181-184. PubMed ID: 33513653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial.
    Behr J; Neuser P; Prasse A; Kreuter M; Rabe K; Schade-Brittinger C; Wagner J; Günther A
    BMC Pulm Med; 2017 Sep; 17(1):122. PubMed ID: 28877715
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.